Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995049 | 1.00 | TRPV1 (0.51) | TRPV1EPHX2RAB9AMAPTCNR2 | |
| Hydrochloric Acid SCHEMBL3010863 | 0.99 | TRPV1 (0.51) | TRPV1EPHX2RAB9AMAPTCNR2 | |
| Hydrochloric Acid SCHEMBL3010859 | 0.99 | TRPV1 (0.51) | TRPV1EPHX2RAB9AMAPTCNR2 | |
| SCHEMBL3003397 | 0.88 | NPY5R (0.48) | TRPV1EPHX2RAB9AMAPTNPY5R | |
| SCHEMBL3003400 | 0.88 | NPY5R (0.48) | TRPV1EPHX2RAB9AMAPTNPY5R | |
| Hydrochloric Acid SCHEMBL3011727 | 0.88 | NPY5R (0.47) | TRPV1EPHX2RAB9AMAPTNPY5R | |
| Hydrochloric Acid SCHEMBL3011728 | 0.88 | NPY5R (0.47) | TRPV1EPHX2RAB9AMAPTNPY5R | |
| SCHEMBL3010756 | 0.86 | NPY5R (0.46) | NPY5RKCNH2ADRA1AKDM4EPOLB | |
| SCHEMBL3005653 | 0.86 | NPY5R (0.46) | NPY5RKCNH2ADRA1AKDM4EPOLB | |
| Hydrochloric Acid SCHEMBL3008669 | 0.85 | NPY5R (0.45) | NPY5RKCNH2ADRA1AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | claimed |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| EP-2121673-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008092887-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | NPY5R, NPY1R, NPY4R | TRPV1 1252/4885EPHX2 3194/4885RAB9A 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.